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To the editor, 
 
We report the case of a 45-year-old homosexual man who was diagnosed with HIV-1 
infection (nadir CD4 count 138 cells/μl) upon presentation with Kaposi’s sarcoma 
(KS, ACTG stage T0 I1 S0, Fig. 1A). KS lesions resolved following initiation of 
combination antiretroviral therapy (ART) with tenofovir, emtricitabine and efavirenz 
combined with local radiotherapy for cosmesis. Persistent generalised 
lymphadenopathy was also noted at presentation, but biopsy of an axillary lymph 
node was benign. The patient had an appropriate response to ART, achieving 
complete viral suppression and immune reconstitution (CD4 334 cells/μl) within 6 
months. 
Eight months later he presented with nephrotic-range proteinuria (serum albumin 26 
mg/dl, urine protein 14 g/l) secondary to histologically proven membranous 
glomerulonephritis, in association with fever, systemic upset and elevated 
inflammatory markers. Serology for hepatitis B, C and syphilis was negative and 
tenofovir was switched to abacavir. A repeat groin lymph node biopsy revealed 
Castleman’s disease (Fig. 1B), and quantitative polymerase chain reaction (qPCR) 
for human herpes virus 8 (HHV8) DNA was 47,000 copies/ml. He was treated initially 
with valganciclovir 900mg b.d. for 3 months with minimal impact on HHV8 replication, 
and rituximab (750mg weekly for one month then monthly for 3 months) was 
introduced.  
There was a clinical response with resolution of proteinuria and reduction of 
lymphadenopathy, however HHV8 replication, anaemia and elevated C-reactive 
protein persisted. Surveillance imaging approximately 6 months later showed further 
improvement with complete resolution of adenopathy but identified a new 15mm liver 
lesion. Histological examination of this lesion revealed an extracavitary primary 
effusion lymphoma (PEL, Fig. 1C). No additional foci were observed by 18-
fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) 
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and cerebrospinal fluid cytological examination was normal. He was treated with six 
cycles of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) 
chemotherapy with intrathecal methotrexate, resulting in a complete response and no 
recurrence of HHV-8 viral replication in blood up to 3 years later (Fig. 1D). 
This case neatly illustrates the spectrum of HHV-8-associated malignancy that 
manifests in patients with HIV-1, and raises some interesting points regarding 
diagnosis and management. Surprisingly, this is the first published report of 
metachronous KS, MCD and PEL in a person living with HIV, although the 
coexistence of KS and MCD [1] or MCD and PEL [2] is not unusual. These disorders 
are aetiologically linked to the gamma herpes virus HHV8 (previously known as 
Kaposi sarcoma-associated herpesvirus, KSHV). MCD and PEL are associated with 
lytic replication, higher levels of the virus detected in plasma, and the paracrine 
effects of oncogenic viral proteins homologous to interleukin-6, Bcl-2 and several 
others [3]. KS, MCD and PEL occur at considerably higher frequency in patients with 
HIV-1 although they have an inconsistent relationship with immunosuppression: KS 
and PEL are associated with low CD4 counts; MCD, which follows a relapsing-
remitting course with episodes of systemic inflammation, is unrelated to the degree of 
immunosuppression and often develops following ART initiation [4]. Thus while the 
incidence of KS in the post-ART era has fallen dramatically, the incidence of MCD is 
stable or increasing [3]. 
Quantification of HHV8 replication by qPCR in plasma or mononuclear cells has an 
important role in diagnosis, prognosis and monitoring of treatment response in HHV-
8-associted malignancies in HIV, particularly MCD. For example, the presence of 
high plasma HHV8 DNA levels in patients with KS should prompt a diagnostic search 
for synchronous MCD [5]. HHV-8 DNA > 40,000 copies/ml was associated with risk of 
death in an HIV-MCD cohort [6], and a rising HHV8 level appeared to predict the 
occurrence of symptomatic episodes [7]. The role of HHV8 monitoring in PEL is 
unclear [3]. As demonstrated here, valganciclovir has only a modest impact on HHV8 
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replication kinetics in vivo [3], and remission rates in MCD are inferior to the anti-
CD20 monoclonal antibody (mAb) rituximab [3] – which remains the mainstay of 
therapy, with 5 year relapse-free survival of 82% (CI 72-92%) [8]. Tocilizumab, an 
interleukin-6 receptor specific mAb, has shown promise [9, 10], but no randomised 
trial evidence is available. An association between MCD and nephrotic syndrome has 
been reported previously [11-13] and warrants further investigation.  
Although the metachronous presentation might suggest an unusually oncogenic 
strain of HHV8, no material was available for viral sequencing. Moreover, we have 
not yet explored whether an additional host defect of innate or adaptive antiviral 
immunity may be involved. Nevertheless, this case serves to illustrate the range of 
HHV8-associated pathology in the context of HIV, underscoring the importance of 
quantifying HHV8 viral load in KS patients where additional HHV8-associated 
lymphoproliferative disorders are suspected, and in assessing response to therapy in 
MCD/PEL.  
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Figure 1 
Haematoxylin & eosin (left panels) and human herpes virus 8 (HHV8) immunostain 
(right panels) of: A) skin biopsy demonstrating Kaposi sarcoma; B) Lymph node 
biopsy demonstrating multicentric Castleman’s disease (MCD); C) Liver lesion biopsy 
demonstrating extracavitory primary effusion lymphoma (PEL). D) Time-course of 
laboratory parameters relative to treatment regimen (filled blocks). CHOP = 
cyclophosphamide, doxorubicin, vincristine and prednisolone with intrathecal 
methotrexate chemotherapy.   
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